Success for iPSC therapy in Parkinson’s monkey model

Induced pluripotent stem cell-derived dopaminergic progenitor cells have been shown to survive and be functional as midbrain dopaminergic neurons in a primate model of Parkinson’s disease.

Go to the profile of RegMedNet
Sep 01, 2017
0
0
Upvote 0 Comment

Researchers from Kyoto University (Japan) have shown that human induced pluripotent stem (iPS) cell-derived dopaminergic progenitor cells can survive and function as midbrain dopaminergic neurons in a primate model of Parkinson’s disease. The first study of its kind, this new research marks a major breakthrough in bringing iPS cell-based therapies for neurodegenerative disease closer to the clinic.

Read the full article on NeuroCentral

Go to the profile of RegMedNet

RegMedNet

eCommunity, Future Science Group

RegMedNet is a networking site where users can share their knowledge and insights. This profile will share some content and updates from the RegMedNet team, including webinars, news and journal articles.

No comments yet.